40 results on '"Furtek, Christine"'
Search Results
2. Progression from Prodromal Alzheimer’s Disease to Mild Alzheimer’s Disease Dementia in the Verubecestat APECS Study: Adjudicating Diagnostic Transitions
3. Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimer’s disease
4. Epidemiology of Treatment-Resistant Depression in the United States
5. Retinal Optical Coherence Tomography Metrics Are Unchanged in Verubecestat Alzheimer’s Disease Clinical Trial but Correlate with Baseline Regional Brain Atrophy
6. Cognitive outcomes in trials of two BACE inhibitors in Alzheimer's disease
7. Additional file 5: of Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimerâ s disease
8. An observer-blinded study of 1% permethrin creme rinse with and without adjunctive combing in patients with head lice
9. Safety, Tolerability, and Pharmacokinetics of Escalating High Doses of Ivermectin in Healthy Adult Subjects
10. P1‐044: VERUBECESTAT DISEASE PROGRESSION MODELING FROM APECS, A PHASE 3 TRIAL IN PRODROMAL ALZHEIMER'S DISEASE: NO DOSE‐ AND EXPOSURE‐DEPENDENCY IN CLINICAL ENDPOINTS
11. FTS3-01-05: FURTHER ANALYSES OF COGNITIVE OUTCOMES IN THE APECS PHASE-3 TRIAL OF VERUBECESTAT IN PRODROMAL AD
12. P1‐042: NEUROFIBRILLARY TANGLE IMAGING WITH [ 18 F]MK‐6240 IN APECS, A PHASE 3 TRIAL IN PRODROMAL ALZHEIMER'S DISEASE PATIENTS
13. Randomized Trial of Verubecestat for Prodromal Alzheimer’s Disease
14. Pharmacokinetics of Intravenous and Oral Losartan in Patients with Heart Failure
15. DuP 532, an angiotensin II receptor antagonist: First administration and comparison with losartan
16. P4‐013: DESIGN OF A PHASE‐3 TRIAL (APECS) TO EVALUATE THE BACE INHIBITOR VERUBECESTAT IN PRODROMAL AD
17. Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer’s Disease
18. VERUBECESTAT DISEASE PROGRESSION MODELING FROM APECS, A PHASE 3 TRIAL IN PRODROMAL ALZHEIMER’S DISEASE: NO DOSE- AND EXPOSURE-DEPENDENCY IN CLINICAL ENDPOINTS
19. NEUROFIBRILLARY TANGLE IMAGING WITH [18F]MK-6240 IN APECS, A PHASE 3 TRIAL IN PRODROMAL ALZHEIMER’S DISEASE PATIENTS
20. FURTHER ANALYSES OF COGNITIVE OUTCOMES IN THE APECS PHASE-3 TRIAL OF VERUBECESTAT IN PRODROMAL AD
21. P4-380: BACE Inhibitor Verubecestat (MK-8931): Baseline Characteristics for Participants Enrolled in the Phase II/III Epoch Alzheimer’S Disease Trial
22. DESIGN OF A PHASE-3 TRIAL (APECS) TO EVALUATE THE BACE INHIBITOR VERUBECESTAT IN PRODROMAL AD
23. BACE INHIBITOR VERUBECESTAT (MK-8931): BASELINE CHARACTERISTICS FOR PARTICIPANTS ENROLLED IN THE PHASE II/III EPOCH ALZHEIMER’S DISEASE TRIAL
24. FAMOTIDINE/ANTACID COMBINATION TABLETS ARE MORE EFFECTIVE FOR THE TREATMENT OF HEARTBURN THAN EITHER COMPONENT ALONE
25. COMPARISON OF THE ONSET OF THE ACID-REDUCING EFFECT OF FAMOTIDINE/ANTACID COMBINATION TABLETS, OMEPRAZOLE 20 MG, AND PLACEBO ON GASTRIC PH PROFILES IN HEALTHY VOLUNTEERS
26. Effect of Within-Household Reinfestation on Design Sensitivity
27. An improved method for the simultaneous determination of losartan and its major metabolite, EXP3174, in human plasma and urine by high-performance liquid chromatography with fluorescence detection
28. Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans
29. The pharmacokinetics of losartan in renal insufficiency
30. Simultaneous determination of a novel angiotensin II receptor blocking agent, losartan, and its metabolite in human plasma and urine by high-performance liquid chromatography
31. DuP 532, an angiotensin II receptor antagonist: First administration and comparison with losartan*.
32. P1‐042: NEUROFIBRILLARY TANGLE IMAGING WITH [18F]MK‐6240 IN APECS, A PHASE 3 TRIAL IN PRODROMAL ALZHEIMER'S DISEASE PATIENTS.
33. Additional file 2: of Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimerâ s disease
34. Additional file 3: of Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimerâ s disease
35. Additional file 2: of Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimerâ s disease
36. Additional file 3: of Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimerâ s disease
37. Additional file 4: of Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimerâ s disease
38. Additional file 1: of Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimerâ s disease
39. Additional file 4: of Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimerâ s disease
40. Additional file 1: of Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimerâ s disease
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.